Parameter
| Biomarker | LAMC2+PTX3 | Full name | Laminin subunit gamma-2 + Pentraxin 3 | Molecular Type | Protein combination |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Early diagnostic aid | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Serum (immunoassay, mass spectrometry) | ||
| Pathobiological Mechanisms | LAMC2 participate in extracellular matrix formation, PTX3 involved in inflammation and angiogenesis, were KRAS G12V related proteins, expressed in PDAC early rise | ||||
| Clinical Availability Status | Clinical research phase: It can improve the diagnostic sensitivity of CA19-9, and has supplementary value for patients with low expression of CA19-9 | ||||
| Notes and Dynamics | It is related to KRAS mutation status and can be detected in the circulation of patients with early PDAC, which provides a basis for molecular typing | ||||